CJC-1295 / ipamorelin
Insufficient evidence for this compound
Research-only / investigational — not FDA approved
Investigational; no FDA-approved drug label is established for this entry. Source: FDA: safety concerns for nominated peptide substances
Also listed as: CJC-1295, ipamorelin
What it is
CJC-1295 is a growth hormone-releasing hormone analog. The cited human study evaluated CJC-1295 alone. Source: Human study: growth hormone secretion during CJC-1295 exposure
What it has been studied for
CJC-1295 alone: growth hormone secretion in healthy men. Source: Human study: growth hormone secretion during CJC-1295 exposure
Ipamorelin: FDA evaluated growth hormone-related uses and found insufficient effectiveness data. Source: FDA review of ipamorelin-related substances
Mechanism
CJC-1295 stimulates growth hormone release; measured hormone changes do not establish a clinical benefit. Source: Human study: growth hormone secretion during CJC-1295 exposure
Documented dosing
No applicable general-use human dose range, frequency or cycle is documented here. Numbers from other routes, formulations or conditions are not interchangeable.
Pairings & cautions
No evidence-based peptide pairing is specified in this entry.
FDA reports limited clinical safety data and adverse events for these substances. Source: FDA: safety concerns for nominated peptide substances
These are selected considerations, not a complete safety review. Discuss the full source and your medications with your prescriber.
Sources
- Human study: growth hormone secretion during CJC-1295 exposure · Research publication
- FDA review of ipamorelin-related substances · Clinical / regulatory reference
- FDA: safety concerns for nominated peptide substances · Clinical / regulatory reference